Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial

Core Insights - Corvus Pharmaceuticals presented final data from its Phase 1/1b trial of soquelitinib for T cell lymphoma, showing promising median progression-free survival (PFS) of 6.2 months and median overall survival (OS) of 28.1 months, indicating potential as a new treatment option [1][2][5] Group 1: Clinical Trial Results - The Phase 1 trial enrolled 75 patients with various T cell lymphomas, with a median of 3 prior therapies, and only 31% achieving an objective response to their last therapy [2][4] - In the 200 mg twice-daily cohort, 6 patients achieved complete responses, with an objective response rate of 37.5% among those with 1 to 3 prior therapies [4] - The trial demonstrated no dose-limiting toxicities or significant adverse events, indicating a favorable safety profile for soquelitinib [4] Group 2: Mechanism of Action - Soquelitinib operates through ITK inhibition, affecting T cell receptor signaling and promoting Th1 differentiation while blocking Th2 and Th17 pathways [3][8] - Biomarker studies showed an increase in Th1 cells and a reduction in IL-5, supporting the drug's immunological effects [9] Group 3: Future Development Plans - The company is advancing soquelitinib into a registration Phase 3 trial for relapsed/refractory peripheral T cell lymphoma (PTCL), with plans to enroll 150 patients [5][11] - Corvus is also exploring soquelitinib's potential in atopic dermatitis and other immune and inflammatory diseases, with additional data expected in early 2026 [5][7]